Verseau Therapeutics

Verseau Therapeutics

Biotechnology, 47 Wiggins Ave, Bedford, Massachusetts, 01730, United States, 11-50 Employees

verseautx.com

  • LinkedIn

phone no Phone Number: 78********

Who is VERSEAU THERAPEUTICS

Verseau is focused on developing the next major wave of cancer immunotherapies directed at a broad and potent reprogramming of the tumor microenvironment to attack tumors. This is accompl...

Read More

map
  • 47 Wiggins Ave, Bedford, Massachusetts, 01730, United States Headquarters: 47 Wiggins Ave, Bedford, Massachusetts, 01730, United States
  • 2017 Date Founded: 2017
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8733

checked-icon Does something look wrong? Fix it. | View contact records from VERSEAU THERAPEUTICS

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Verseau Therapeutics

Answer: Verseau Therapeutics's headquarters are located at 47 Wiggins Ave, Bedford, Massachusetts, 01730, United States

Answer: Verseau Therapeutics's phone number is 78********

Answer: Verseau Therapeutics's official website is https://verseautx.com

Answer: Verseau Therapeutics's revenue is $5 Million to $10 Million

Answer: Verseau Therapeutics's SIC: 8733

Answer: Verseau Therapeutics has 11-50 employees

Answer: Verseau Therapeutics is in Biotechnology

Answer: Verseau Therapeutics contact info: Phone number: 78******** Website: https://verseautx.com

Answer: Verseau is focused on developing the next major wave of cancer immunotherapies directed at a broad and potent reprogramming of the tumor microenvironment to attack tumors. This is accomplished by stimulating macrophages to shift their phenotype from immunosuppressive to a pro-inflammatory, anti-tumor state in a process called macrophage repolarization. Verseau developed a unique target discovery engine that leveraged patient data and computational biology to discover and validate over 20 novel macrophage targets. Verseaus first-in-class monoclonal antibody candidates, VTX-0811 targeting PSGL-1 and VTX-1218 targeting VSIG4, are in late preclinical development and progressing toward clinical trials.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access